Clinical Trial Update: Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating MM-151 in combination with nal-IRI, 5-FU, and leucovorin for RAS/RAF wild-type metastatic colorectal cancer has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-FU (5-fluorouracil)
• Leucovorin (folinic acid)
• MM-151
• Nal-IRI (nanoliposomal irinotecan)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: WITHDRAWN